1 / 4

Addressing CMV Retinitis and Hepatitis C Co-Infections: Advances and Opportunities

This session focuses on the importance of co-infections despite ART success, challenges in diagnosis and treatment, MSF experience sharing, and opportunities for improving access. Experts discuss CMV retinitis and HCV burden, challenges, and potential solutions.

sileas
Download Presentation

Addressing CMV Retinitis and Hepatitis C Co-Infections: Advances and Opportunities

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Advances and Opportunities to Address Co-Infections: CMV Retinitis and Hepatitis C IAS 2013 Sunday 30 July

  2. Why Co-Infections…? • Co-infections remain important despite the success of ART roll out • Late presenters - CMV • Important co-infection even in face of ART - HCV • Need for additional political will and funding • Testing and treatment often not supported • Few guidelines • Regional importance • Key opportunities • CMV: Potential for decentralization of screening, diagnosis and treatment • HCV: Potential for paradigm shifting pipeline regimens

  3. Goals: CMV and HCV • Examine burden • Explore challenges in diagnosis and treatment • Share MSF experience • Highlight critical and timely opportunities to improve access to diagnosis, treatment and care

  4. Agenda • CMV Retinitis – the neglected co-infection • KhinNyein Chan, • Nathan Ford • Peter Saranchuk • AraxBozadjian **Respondant: Dr. Rewari • Hepatitis C – Increasing recognition of importance • Nicolas Durier • Isabelle Andrieux-Meyer • ManicaBalasegaram **Respondant: ShibaPhurailatpam

More Related